PMID- 35257383
OWN - NLM
STAT- MEDLINE
DCOM- 20220727
LR  - 20220727
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 7
DP  - 2022 Jul
TI  - Osteoporosis or fracture risk associated with thiazolidinedione and proton pump 
      inhibitor co-administration in patients with type 2 diabetes mellitus.
PG  - 1028-1035
LID - 10.1111/jcpt.13640 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Thiazolidinedione (TZD) and proton pump inhibitor 
      (PPI) belong to classes of drugs that affect bone metabolism; however, few 
      studies have investigated the effects of these drugs on bone metabolism. The aim 
      of this study was to assess the risk of osteoporosis or fracture in patients with 
      type 2 diabetes mellitus (T2DM) co-administered TZD and PPIs. METHODS: This 
      retrospective cohort study was conducted using the National Sample Cohort 
      database from 2003 to 2013. We included adult patients with T2DM who were 
      prescribed TZD and PPIs together for the first time. The Cox proportional hazard 
      model was used to determine the risk ratio of fracture or osteoporosis in the 
      co-administration cohort (TZD + PPI) compared with the TZD-only group (TZD). We 
      adjusted for age, sex, use of other medications and other diseases that affect 
      the bone. RESULTS AND DISCUSSION: Of 9073 patients administered TZD, the number 
      of eligible patients was 7240 (545 TZD + PPI, 6695 TZD-only). After 1:3 
      propensity score matching, 545 patients remained in the TZD + PPI group and 1635 
      in the TZD-only group. The risk of osteoporosis or fracture was significantly 
      higher in the TZD + PPI cohort than in the TZD-only cohort. The adjusted hazard 
      ratio (HR) for fracture or osteoporosis was 1.47 (95% CI 1.05-2.07). TZD and PPI 
      use in women were associated with an increased risk of skeletal outcomes. WHAT IS 
      NEW AND CONCLUSION: TZD and PPI use were associated with an increased risk of 
      osteoporosis or fracture in patients with T2DM.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Ock, Miyoung
AU  - Ock M
AD  - College of Pharmacy, Sookmyung Women's University, Seoul, South Korea.
FAU - Lee, Sera
AU  - Lee S
AD  - College of Pharmacy, Sookmyung Women's University, Seoul, South Korea.
FAU - Kim, Hyunah
AU  - Kim H
AUID- ORCID: 0000-0002-5533-2040
AD  - College of Pharmacy, Sookmyung Women's University, Seoul, South Korea.
AD  - Drug Information Research Institute, Sookmyung Women's University, Seoul, South 
      Korea.
LA  - eng
GR  - NRF-2017R1A2B1001913/National Research Foundation of Korea (NRF)/
PT  - Journal Article
DEP - 20220307
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Female
MH  - *Fractures, Bone/chemically induced/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - *Osteoporosis/chemically induced/drug therapy/epidemiology
MH  - Proton Pump Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Thiazolidinediones/adverse effects
OTO - NOTNLM
OT  - drug-drug interaction
OT  - fracture
OT  - osteoporosis
OT  - proton pump inhibitor
OT  - thiazolidinedione
EDAT- 2022/03/09 06:00
MHDA- 2022/07/28 06:00
CRDT- 2022/03/08 05:41
PHST- 2022/01/14 00:00 [revised]
PHST- 2022/01/08 00:00 [received]
PHST- 2022/01/25 00:00 [accepted]
PHST- 2022/03/09 06:00 [pubmed]
PHST- 2022/07/28 06:00 [medline]
PHST- 2022/03/08 05:41 [entrez]
AID - 10.1111/jcpt.13640 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Jul;47(7):1028-1035. doi: 10.1111/jcpt.13640. Epub 2022 
      Mar 7.